Dose-response study of nebulised nedocromil sodium in exercise induced asthma

M K ALBAZZAZ, M G NEALE, K R PATEL

From the Department of Respiratory Medicine, Western Infirmary, Glasgow, and the Department of Clinical Pharmacology, Fisons PLC, Loughborough

ABSTRACT Ten patients with exercise induced asthma, in whom inhaled nedocromil sodium 4 mg by metered dose inhaler attenuated the exercise fall in forced expiratory volume in one second (FEV₁) by at least 40%, participated in a double blind dose response study to compare the protective effect of nedocromil sodium given 15 minutes before exercise challenge via a nebuliser (Wright) in concentrations of 0·5, 5, 10, and 20 mg/ml with that of placebo (saline). Response was assessed as the maximum fall in FEV₁ after the patient had run on a treadmill for six to eight minutes. Plasma concentrations of nedocromil sodium were measured at the time of challenge. After exercise challenge the mean (SEM) maximum percentage falls in FEV₁ were 30·3 (1·6) for the control run and 28·0 (4·1) after placebo. The percentage fall was attenuated by pretreatment with all concentrations of nedocromil sodium to 12·8 (2·8), 11·2 (2·1), 12·8 (2·1), and 14·1 (3·5) for the 0·5, 5, 10, and 20 mg/ml concentrations respectively (p < 0·001). There were no significant differences between the different nedocromil concentrations. Mean plasma concentrations of nedocromil sodium were proportional to dose. Thus concentrations of nebulised nedocromil sodium that ranged from 0·5 to 20 mg/ml gave a similar degree of protection (50–60%) against exercise induced asthma. This appears to be the maximum protection that can be achieved with nedocromil sodium and is similar to the protection obtained with 4 mg nedocromil administered by metered dose aerosol.

Introduction

Nedocromil sodium is the salt of a pyranoquinoline dicarboxylic acid that has been developed for the treatment of reversible obstructive airways disease.1 2 It is thought to reduce inflammation.2 In vitro it prevents the release of histamine and other mediators from lung mast cells3 and in asthmatic patients inhalation of 4 mg nedocromil sodium is effective in blocking allergen induced bronchoconstriction for at least three4 and possibly up to six hours.5 The drug also offers partial protection against bronchoconstriction due to sulphur dioxide,6 fog,7 cold air,8 adenosine,9 and exercise.10 In clinical trials 4 mg inhaled nedocromil sodium was more effective than placebo in controlling symptoms and improving lung function in adult asthmatic patients with both twice and four times daily dosing.11-14 Despite numerous studies with various bronchial provocation tests comparatively little is known of the dose-response characteristics of nedocromil sodium.

The aim of the present study was to examine the dose-response characteristics of nedocromil sodium over a range of concentrations in patients with exercise induced asthma, a nebulised solution being used to allow greater flexibility in dosing. Plasma concentrations of the drug were measured as a check on absorbed dose.

Methods

Twelve men with extrinsic asthma were screened and 10 of these, aged 17–54 (mean 37, SEM 4) years, were enrolled. The selected patients had previously been shown to have exercise induced asthma with a fall in FEV₁ of more than 20% after exercise challenge. They also had at least 40% protection against the fall following treatment with nedocromil sodium aerosol (4 mg). Patients taking sodium cromoglycate or inhaled bronchodilators discontinued these for 24 hours and 12 hours respectively before each exercise.
Dose-response study of nebulised nedocromil sodium in exercise induced asthma

Inhaled corticosteroids were continued during the study. None of the patients was taking oral steroids, theophylline preparations, or antihistamines. Informed consent was obtained and the study was approved by the hospital ethics committee.

FEV₁ was measured with a dry wedge spirometer (Vitalograph, Buckingham) and the best of three attempts was recorded for analysis. The exercise test consisted of steady state running on an inclined treadmill for six to eight minutes with a submaximal work load, adjusted to produce over 80% of the maximum predicted heart rate. The temperature on the study days was 20–22°C and the relative humidity 40–60%. The same treadmill setting and exercise duration were used for each test in a given patient. The series of six challenge tests on each patient was completed within 20 days.

The effect of two puffs (4 mg) of nedocromil sodium from a standard metered dose inhaler (Tilade) on exercise challenge was tested during the first visit. On the subsequent visits the patient received each of four concentrations of nedocromil (0.5, 5, 10, and 20 mg/ml) and placebo by nebuliser in a double blind randomised fashion. The solutions were delivered via a Wright nebuliser driven by compressed air at a flow rate of 9 l/min (18 lb/in², 124 kPa). Dosing started 20 minutes before exercise challenge. All inhalations were carried out with the patient breathing tidally for five minutes, during which time about 1 ml of solution was nebulised. The estimated amounts of drug nebulised were 0.5, 5, 10, and 20 mg. FEV₁ was recorded before dosing and 5 and 15 minutes after the end of dosing (that is, immediately before exercise) and then one, two, five, 10, 15, and 30 minutes after exercise. The FEV₁ response to exercise was expressed as the maximal fall in FEV₁ from the post-drug baseline. The degree of protection was calculated as:

\[(\text{Maximum control fall} - \text{maximum test fall}) \times 100\%\]

Venous blood samples (5 ml) were taken from the antecubital vein immediately before each exercise test (that is, 20 minutes after the start of nebulisation). The blood was centrifuged immediately and the plasma separated and stored at −20°C until analysed. Plasma concentrations of nedocromil sodium were determined by a sensitive radioimmunoassay,¹ which had a suitable range and linearity for the concentrations measured in this study.

**Analysis**

Responses to each drug concentration were compared by analysis of variance with repeated measures and paired Student's t test. A p value of 0.05 was accepted as significant.

**Results**

There were no significant differences between mean baseline FEV₁ values before and after any of the treatments (table 1). The work load and maximum heart rate achieved by each subject in the control test are given in table 2. After exercise challenge the mean (SEM) maximum percentage falls in FEV₁ were similar for control (30.3 (1.6)) and placebo (28.0 (4.1)); all active treatments showed much smaller percentage falls in FEV₁, with values of 10.6 (2.6), 12.8 (2.8), 11.2 (2.1), 12.8 (2.1), and 14.1 (3.5) for the 4 mg inhaler dose and the 0.5, 5, 10, and 20 mg/ml nebulised solution (table 2). The exercise induced fall in FEV₁ was inhibited by all concentrations of nedocromil sodium; the maximum falls were significantly different from those after placebo (p < 0.001). There were no significant differences between active treatments.

The time course of change in FEV₁ is shown in the figure. Significant differences between placebo and active treatments were found at all time points after exercise except the first. There were no significant differences between active treatments. The recovery in FEV₁ was quicker with active treatments than with placebo. Thirty minutes after exercise the FEV₁ had returned to baseline value after nedocromil whereas with placebo it was still more than 15% below the prechallenge value (figure).

The protective effect of nedocromil sodium (4 mg) from a metered dose inhaler was similar to that produced by all the nebulised concentrations and was more than 50% in all cases. The percentage protection was 8.9 (12.0), 58.8 (8.9), 65.0 (6.3), 58.8 (7.7) and 56.7 (9.0) for placebo and the 0.5, 5, 10, and 20 mg/ml nebulised solution.

Nebulised salbutamol was required after challenge.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Mean (SEM) baseline values of FEV₁ (l) before and after administration of placebo and nedocromil sodium in 10 patients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Before</td>
<td>3.38 (0.31)</td>
</tr>
<tr>
<td>After</td>
<td>3.33 (0.35)</td>
</tr>
</tbody>
</table>
Table 2  Age, workload and heart rate, and maximal percentage fall in FEV, after exercise challenge after placebo and after nedocromil sodium nebulised at different concentrations and from a pressurised inhaler in 10 patients

<table>
<thead>
<tr>
<th>Patient no</th>
<th>Age (y)</th>
<th>Work load (kpm/min)</th>
<th>Heart rate (beats/min)*</th>
<th>Control</th>
<th>Placebo</th>
<th>Nebulised nedocromil concentration (mg/ml)</th>
<th>4 mg nedocromil by metered dose inhaler</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>49</td>
<td>1316</td>
<td>150 (178)</td>
<td>28-4</td>
<td>6-1</td>
<td>0-0</td>
<td>2-3</td>
</tr>
<tr>
<td>2</td>
<td>28</td>
<td>2038</td>
<td>167 (192)</td>
<td>35-8</td>
<td>27-9</td>
<td>12-8</td>
<td>14-9</td>
</tr>
<tr>
<td>3</td>
<td>35</td>
<td>1750</td>
<td>162 (187)</td>
<td>27-0</td>
<td>27-1</td>
<td>22-8</td>
<td>11-2</td>
</tr>
<tr>
<td>4</td>
<td>49</td>
<td>1371</td>
<td>150 (178)</td>
<td>34-9</td>
<td>38-4</td>
<td>27-4</td>
<td>18-3</td>
</tr>
<tr>
<td>5</td>
<td>36</td>
<td>1579</td>
<td>170 (187)</td>
<td>37-9</td>
<td>27-9</td>
<td>8-4</td>
<td>18-1</td>
</tr>
<tr>
<td>6</td>
<td>24</td>
<td>1603</td>
<td>170 (194)</td>
<td>21-5</td>
<td>15-9</td>
<td>3-2</td>
<td>4-6</td>
</tr>
<tr>
<td>7</td>
<td>17</td>
<td>1457</td>
<td>194 (199)</td>
<td>30-4</td>
<td>50-3</td>
<td>8-6</td>
<td>7-8</td>
</tr>
<tr>
<td>8</td>
<td>54</td>
<td>967</td>
<td>164 (175)</td>
<td>28-8</td>
<td>18-7</td>
<td>8-3</td>
<td>1-8</td>
</tr>
<tr>
<td>9</td>
<td>43</td>
<td>1758</td>
<td>166 (182)</td>
<td>26-2</td>
<td>26-8</td>
<td>19-3</td>
<td>16-9</td>
</tr>
<tr>
<td>10</td>
<td>35</td>
<td>1714</td>
<td>168 (187)</td>
<td>31-4</td>
<td>41-2</td>
<td>17-1</td>
<td>16-0</td>
</tr>
</tbody>
</table>

Mean: 37 1553 166 (186) 30-3 28-0
SEM: 4 93 14 (3) 1-6 4-1

*Age-predicted maximum heart rate in parentheses and calculated by the formula 210 - 0.65 × age (y). kpm—kilopond.

Discussion

This study shows that nebulised nedocromil sodium administered 15 minutes before exercise challenge to susceptible patients in concentrations from 0.5 mg/ml to 20 mg/ml is effective in attenuating the fall in FEV, with no significant difference in the inhibitory effect between the four concentrations. Protection was about 50%, which is similar to that afforded by 4 mg nedocromil from a metered dose inhaler. Although there was no difference between the protection afforded by the different nebuliser concentrations, plasma concentrations were related to nebuliser concentration and hence to dose. In this respect 4 mg nedocromil from the metered dose inhaler produced plasma concentrations similar to the 5 mg/ml nebuliser concentration, suggesting that the dose absorbed must be similar. Previous studies have shown a protective effect of nedocromil sodium from a metered dose inhaler in exercise challenge.

In this study the response to nedocromil was not dose dependent over the range of doses studied. This contrasts with earlier observations with sodium cromoglycate in exercise challenge. The difference may reflect the fact that nedocromil sodium is more potent than sodium cromoglycate, as shown in some in vitro studies and in vivo models, so that all doses lie near the top of the dose-response curve. Use of lower concentrations 15 minutes before challenge would probably result in a dose related response. Duration of effect might be expected to vary with dose; this is under investigation.

Exercise induced bronchoconstriction is a well recognised phenomenon in asthma and, although the exact mechanism of its pathogenesis is not clear, it provides a relatively safe method for assessing the effect of various drugs. The coefficient of variation was calculated to vary from 12% to 16% in a recent study in our department, though intrasubject variation has been reported to be as high as 25%. Release of mast...
cell associated mediators, such as high molecular weight neutrophil chemotactic factor\(^{24}\) and histamine,\(^{25}\) during exercise has been reported. Sodium cromoglycate prevents both the development of exercise asthma and the accompanying mediator release.\(^{25}\) This is thought to reflect, at least in part, its action as a mast cell stabiliser. Animal studies have identified a heterogeneity of mast cells with connective tissue and mucosal subtypes.\(^{26,27}\) Nedocromil sodium stabilises both.\(^{3}\) This property may account for its ability to attenuate exercise asthma. The mechanisms of action of nedocromil sodium and sodium cromoglycate in the response to exercise challenge and in other models of asthma are not at present clear. There is, however, evidence that nedocromil sodium is more potent than sodium cromoglycate in some models\(^{28,29}\), and the results from this study, even though no direct comparison was made, suggest that nedocromil sodium has a dose-response profile different from that of sodium cromoglycate in exercise challenge, which may be due to greater potency.

References


14 Fyans PG, Chatterjee PC, Chatterjee SS. A trial comparing nedocromil sodium (Tilade) and placebo in the management of bronchial asthma. Clin Allergy 1986;16:505-11.


